In the recently published PARAGLIDE-HF trial, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP levels in comparison to valsartan alone in patients with an EF > 40% and a recent worsening HF event [27]. This evidence concerns the gene NPPB and hydrops fetalis.